Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock

NEW YORK, Feb. 26, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the underwritten public offering […]

Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial

NEW YORK, Feb. 26, 2020 /PRNewswire/ —     Primary endpoints successfully met   Results confirm significant clinical benefits of ORMD-0801 at lower dose treatment   0.95% (0.81% placebo adjusted) A1C reduction in patients treated once daily at 8mg   Excellent safety profile   Paves the way for FDA discussions on Phase 3 Study   […]

Join our mailing list

Skip to content